The purpose of this study is to determine if subjects with symptomatic asthma who are
assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer
asthma attacks than similar subjects assigned to placebo treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Johns Hopkins Bloomberg School of Public Health
Collaborators:
American Lung Association Asthma Clinical Research Centers National Heart, Lung, and Blood Institute (NHLBI)